Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company, announced the full exercise of the over-allotment option by lead underwriter Dominari Securities LLC following its IPO. The underwriters purchased an additional 562,500 shares at $4.00 per share, raising an extra $2.25 million.
The total gross proceeds from the IPO now amount to $17.25 million through the issuance of 4,312,500 total shares. The offering was led by Dominari Securities LLC, with Pacific Century Securities and Revere Securities as co-underwriters. The registration statement became effective on August 12, 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), una società farmaceutica in fase di sviluppo, ha annunciato l’esercizio integrale della opzione di over-allotment da parte del lead underwriter Dominari Securities LLC, dopo l’IPO. Gli underwriter hanno acquistato ulteriori 562.500 azioni a 4,00 USD ciascuna, raccogliendo ulteriori 2,25 milioni di USD.
Le proventi lordi totali dall’IPO ammontano ora a 17,25 milioni di USD, attraverso l’emissione di 4.312.500 azioni totali. L’offerta è stata guidata da Dominari Securities LLC, con Pacific Century Securities e Revere Securities come co-underwriter. Il filing registrazione è diventato efficace l’12 agosto 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), una empresa farmacéutica en etapa de desarrollo, anunció el ejercicio total de la opción de sobreasignación por parte del suscriptor principal Dominari Securities LLC tras su OPI. Los suscriptores adquirieron 5.6250.000 acciones adicionales a 4,00 USD por acción, recaudando 2,25 millones de USD adicionales.
Los ingresos brutos totales de la IPO ascienden ahora a 17,25 millones de USD mediante la emisión de 4.312.500 acciones en total. La oferta fue liderada por Dominari Securities LLC, con Pacific Century Securities y Revere Securities como co-suscriptores. El registro se volvió efectivo el 12 de agosto de 2025.
Curanex Pharmaceuticals (NASDAQ:CURX)는 개발 단계의 제약 회사로, IPO 이후 주간사인 Dominari Securities LLC의 초과배정 옵션 전액 행사 소식을 발표했습니다. 주관사는 추가로 562,500주를 주당 4.00달러에 매입해 추가로 2.25백만 달러를 모았습니다.
IPO의 총 총매출은 이제 1,7250만 달러로 증가하며, 총 4,312,500주가 발행되었습니다. 이 공모는 Dominari Securities LLC가 주도했고, Pacific Century Securities와 Revere Securities가 공동 주관사로 참여했습니다. 등록서는 2025년 8월 12일에 효력을 발휘했습니다.
Curanex Pharmaceuticals (NASDAQ:CURX), une société pharmaceutique en phase de développement, a annoncé l’exercice total de l’option de surallocation par le chef de syndicat Dominari Securities LLC, après son IPO. Les souscripteurs ont acheté 562 500 actions supplémentaires à 4,00 $ par action, recueillant 2,25 millions de dollars supplémentaires.
Les produits bruts totaux de l’IPO s’élèvent désormais à 17,25 millions de dollars grâce à l’émission de 4 312 500 actions au total. L’offre a été dirigée par Dominari Securities LLC, avec Pacific Century Securities et Revere Securities comme co-syndicataires. La déclaration d’enregistrement est devenue efficace le 12 août 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), ein Pharmaunternehmen in der Entwicklungsphase, gab die vollständige Ausübung der Überzuteilungsoption durch den führenden Underwriter Dominari Securities LLC nach dem IPO bekannt. Die Underwriter kauften zusätzlich 562.500 Aktien zu je 4,00 USD pro Aktie und erhielten damit weitere 2,25 Millionen USD.
Die gesamten Bruttoerlöse aus dem IPO belaufen sich nun auf 17,25 Millionen USD durch die Ausgabe von 4.312.500 Aktien insgesamt. Das Angebot wurde von Dominari Securities LLC geleitet, mit Pacific Century Securities und Revere Securities als Co-Underwritern. Die Registrierungsunterlagen wurden am 12. August 2025 wirksam.
Curanex Pharmaceuticals (NASDAQ:CURX)، شركة أدوية في مرحلتها التطويرية، أعلنت عن التنفيذ الكامل لخيار الإفراط في التخصيص من قبل المكتتب الرئيسي Dominari Securities LLC عقب طرحها العام الأولي. اشترى المكتتبون 562,500 سهم إضافي بسعر 4.00 دولار للسهم، ما أضاف 2.25 مليون دولار إضافية.
إجمالي العائدات الإجمالية من الطرح العام وصل الآن إلى 17.25 مليون دولار من خلال إصدار 4,312,500 سهمًا إجمالًا. كان العرض بقيادة Dominari Securities LLC، مع Pacific Century Securities وRevere Securities كمكتتبان مشاركان. أصبحت بيانات التسجيل سارية المفعول في 12 أغسطس 2025.
Curanex Pharmaceuticals (NASDAQ:CURX)，一家处于开发阶段的药品公司，宣布在首次公开发行（IPO）后，由主承销商 Dominari Securities LLC 完全行使超额配售权。承销商以每股 4.00 美元 的价格再购入 562,500 股，额外募集 2.25 百万美金。
通过发行共 4,312,500 股，IPO 的总毛额现为 1,7250 万美金。本次发行由 Dominari Securities LLC 牵头，Pacific Century Securities 和 Revere Securities 为共同承销商。注册声明于 2025 年 8 月 12 日 生效。
- None.
- Significant shareholder dilution from issuance of 4,312,500 total shares
- Early-stage company status with developmental products indicates high investment risk
Insights
Curanex successfully raised an additional $2.25M through full exercise of IPO over-allotment option, demonstrating strong investor demand.
The full exercise of the over-allotment option by lead underwriter Dominari Securities represents a positive signal for Curanex Pharmaceuticals. The additional sale of 562,500 shares at the $4.00 IPO price brings total gross proceeds to
This development is particularly significant for a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases. The complete exercise of the "greenshoe" option indicates strong initial demand for the IPO that exceeded the initial allocation. Underwriters typically only exercise this option when they believe they can place these additional shares with investors at the offering price.
For Curanex, these additional funds strengthen its balance sheet at a critical early stage, potentially extending its operational runway while pursuing its drug development programs. The successful IPO and over-allotment exercise provide validation of investor interest in the company's approach to botanical drug development for inflammatory conditions.
However, investors should note that as a developmental stage company, Curanex likely faces significant R&D expenses and regulatory hurdles before potentially bringing products to market. The additional capital, while positive, represents just one step in what is typically a lengthy and capital-intensive drug development process for pharmaceutical companies.
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari Securities LLC, which acted as the lead underwriter for the Company’s underwritten initial public offering (the “Offering” or the “IPO”), has exercised in full the over-allotment option the Company granted to the underwriters and purchased additional 562,500 shares of common stock of the Company at the IPO price of
As a result of the sale of these 562,500 shares, the Company has raised an additional
Dominari Securities LLC acted as the lead underwriter for the Offering, with Pacific Century Securities LLC and Revere Securities LLC acting as co-underwriters. The Crone Law Group, P.C. served as counsel to the Company. Sichenzia Ross Ference Carmel LLP served as lead counsel to the underwriters with respect to the Offering.
A registration statement on Form S-1, as amended (File No. 333-282686) relating to the Offering was previously filed with the Securities and Exchange Commission (the “SEC”) and subsequently declared effective by the SEC on August 12, 2025. The Offering was made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus related to the Offering may be obtained from Dominari Securities LLC, 725 5th Avenue, 23rd Floor, New York, NY 10022, or by telephone at (212) 393-4500.
Before you invest in the Company, you should read the final prospectus and other documents the Company has filed with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.
The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The primary indication is moderate to severe ulcerative colitis. The Company will advance its lead botanical drug candidate, Phyto-N, through FDA-required studies, IND submission, and into Phase I clinical trials.
For more information, visit the Company’s website at www.curanexpharma.com.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.
For more information, please contact:
Curanex Pharmaceuticals Inc
Attn: Liqin Xie, Chief Operating Officer
FAQ
How much did Curanex Pharmaceuticals (CURX) raise in their IPO including the over-allotment?
What was the IPO price for Curanex (CURX) shares?
How many additional shares were sold through CURX's over-allotment option?
Who were the underwriters for the Curanex (CURX) IPO?
When did Curanex's (CURX) IPO registration statement become effective?
